Clarity Pharmaceuticals raises AU$121 million

Clarity Pharmaceuticals Limited (ASX: CU6) announced a fully underwritten AU$121 million equity raising comprising a pro rata accelerated non-renounceable entitlement offer and a placement to institutional investors. The company will use these proceeds to advance its clinical portfolio and strengthen the balance sheet.

Post completion of the Offer, Clarity will have a proforma cash balance of AU$153.2 million and it expects to be funded for its current clinical program through to early 2026. This will fund the development of Clarity’s clinical portfolio of products, SAR-bisPSMA, SAR-Bombesin and SARTATE, as the Company progresses towards a number of clinical trial milestones.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com